
Novo Nordisk reported lower BMI after 68 weeks of Wegovy treatment, while saying longer-term effects in children remain unknown.
Novo Nordisk said Wegovy lowered body mass index in children ages 6 to under 12 with obesity in a late-stage trial. At 68 weeks, BMI fell 17.4% among children who stayed on the drug and rose 2.2% among those on placebo.
The estimated average difference between the groups was 19.7 percentage points. Across all 167 children, including those who stopped treatment, Wegovy lowered BMI by an estimated 16.2 percentage points more than placebo.
All participants also received lifestyle changes, including a reduced-calorie diet and increased physical activity. Novo said the drug’s safety and tolerability were consistent with adult trials, with no observed safety concerns related to growth or pubertal development.
The study does not establish whether treating obesity earlier changes its long-term course, Novo medical director Andrea Traina said, calling this an “evidence gap.”
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.